Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal.
Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily.
Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose of metformin hydrochloride gradually.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool.
It is not known whether the active ingredient of the medicine is present in material excreted in the stool. If a patient repeatedly reports finding this medicine in the stool, the healthcare provider should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions).
⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's existing dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg.
⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate.
⦁ When this medicine is administered concomitantly with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse reactions and 6. Interactions.)
Special populations
Renal impairment
Because dose adjustment according to renal function is required, renal function should be assessed before treatment with this medicine and periodically thereafter.
No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows.
- Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine.
The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine must be discontinued immediately.
Elderly
In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.
Improvement of glycemic control in adults with type 2 diabetes
Difficulty controlling blood sugar
type 2 diabetes
cardiovascular disease
View approved original textHide original text
This medication is used to help control blood sugar in adults with type 2 diabetes who are also following dietary and exercise regimens. It specifically helps lower blood sugar effectively by administering empagliflozin and metformin together. It may also have some effect in adults with type 2 diabetes whose blood sugar is not well controlled and have cardiovascular disease, thus it is important to refer to professional guidance. This medication improves blood sugar management and assists in diabetes treatment.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal.
Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily.
Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily.
To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose of metformin hydrochloride gradually.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool.
It is not known whether the active ingredient of the medicine is present in material excreted in the stool. If a patient repeatedly reports finding this medicine in the stool, the healthcare provider should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions).
⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's existing dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg.
⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin.
When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate.
⦁ When this medicine is administered concomitantly with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse reactions and 6. Interactions.)
Special populations
Renal impairment
Because dose adjustment according to renal function is required, renal function should be assessed before treatment with this medicine and periodically thereafter.
No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2].
In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows.
- Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine.
The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine must be discontinued immediately.
Elderly
In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.
Precautions
This medication is used for the treatment of diabetes and should not be used in patients with poor kidney function, acute infections, dehydration, or unstable heart function.
It can rarely cause serious side effects such as lactic acidosis; thus, it is essential to inform a doctor immediately if symptoms such as muscle pain, breathing difficulties, weakness, or abdominal pain occur while taking this medication.
The risk of hypoglycemia may increase when used with insulin or other blood sugar-lowering agents, thus careful monitoring of blood sugar changes is necessary, and medication dosage may require adjustment if needed.
Urinary tract infections or genital infections may occur, so prompt treatment should be sought if any symptoms of infection appear.
This medication may affect kidney function, making regular blood tests to monitor kidney status important.
Moreover, it may lead to a decrease in fluid volume, and caution should be exercised by elderly patients or those with dehydration or low blood pressure.
It is safest to avoid using this medication in pregnant women or those who may become pregnant, as well as in breastfeeding individuals.
Patients scheduled for surgery or undergoing iodine contrast tests should temporarily discontinue the medication and resume it only after confirming normal kidney function.
This medication should not be chewed or crushed and should be swallowed whole; the tablet coating may appear in the stools, but this is normal.
In case of overdose, immediate medical attention should be sought, particularly because symptoms of lactic acidosis may occur.
Excessive alcohol consumption should be avoided while taking this medication, and any unusual symptoms or suspected side effects related to the medication should be promptly discussed with healthcare professionals.
Side effects
Hypoglycemia
urinary tract infection
genital infection
increased urination
decreased and deficiency of vitamin B12
ketoacidosis
lactic acidosis
decreased fluid volume
nausea
vomiting
Show 164 moreCollapse
diarrhea
abdominal pain
loss of appetite
constipation
abnormal liver function tests
hepatitis
taste disturbance
pruritus
rash
urticaria
erythema
angioedema
dysuria
interstitial nephritis
thirst
increased serum lipids
increased serum creatinine
decreased glomerular filtration rate
increased hematocrit
perineal necrosis
chronic gastritis
cerebral infarction
soft tissue infection
pneumonia
ankle fracture
epicondylitis
facial bone fracture
musculoskeletal pain
myocardial infarction
urosepsis
pyelonephritis
headache
dizziness
insomnia
weight loss
constipation
gastritis
oral discomfort
salivary gland pain
sensory impairment
positional dizziness
amnesia
drowsiness
fatigue
peripheral edema
facial edema
fever
facial swelling
chills
strange sensations
edema
pain
pain at the puncture site
vascular stent stenosis
vascular stent thrombosis
increased alanine aminotransferase
increased aspartate aminotransferase
weight gain
abnormal electrocardiogram
decreased hemoglobin
increased hemoglobin
positive Helicobacter test
positive urine red blood cells
urinary stones
hematuria
kidney mass
urinary retention
urinary pain
urinary abnormalities
vulvar pruritus
benign prostatic hyperplasia
erectile dysfunction
atrophic vaginitis
cervical dysplasia
cervical inflammation
scrotal pain
sexual dysfunction
vaginal discharge
hypercholesterolemia
dyslipidemia
hyperglycemia
hyponatremia
dermal cyst
seborrheic dermatitis
atopic dermatitis
diabetic foot
nummular eczema
heat rash
sebaceous gland hyperplasia
lumbar spinal stenosis
myalgia
limb pain
musculoskeletal chest pain
arthralgia
cervical stenosis
fibromyalgia
flank pain
fracture pain
muscle weakness
osteoarthritis
osteoporosis
rotator cuff syndrome
astigmatism
cataract
allergic conjunctivitis
blurred vision
corneal erosion
glaucoma
macular fibrosis
eye discomfort
eye congestion
pathological myopia
retinal detachment
retinal crystals
retinal vein occlusion
macular retinal detachment
eyelid swelling
visual impairment
vitreous floaters
vitreous hemorrhage
epistaxis
asthma
exercise-induced dyspnea
wet cough
allergic rhinitis
residual sputum
cough
skin laceration
contusion
rib fracture
concussion
corneal abrasion
fall
hand fracture
iliotibial band syndrome
open globe injury
pelvic fracture
road traffic accident
splenic injury
sternum fracture
angina
palpitations
Prinzmetal angina
coronary artery disease
tachycardia
arteriosclerosis
deep vein thrombosis
diabetic vascular complications
peripheral arterial obstructive disease
anxiety
depression
sleep disorders
acute cholecystitis
autoimmune hepatitis
cholelithiasis
hepatitis
otalgia
positional vertigo
dizziness
anemia
lymphadenopathy
hypothyroidism
thyroid mass
diabetic foot
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, at room temperature between 1 to 30 degrees Celsius. Proper storage can maintain the medication's effectiveness over time.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.